PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference
PMV Pharmaceuticals (Nasdaq: PMVP) has announced that CEO David H. Mack, Ph.D., will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 2, 2020, at 1:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PMV Pharmaceuticals (Nasdaq: PMVP) has announced that CEO David H. Mack, Ph.D., will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 2, 2020, at 1:00 PM ET. This presentation focuses on the company's pioneering work in precision oncology, targeting p53 mutants, a common mutation in cancer. Interested parties can access the presentation via the company's website. PMV Pharma, based in Cranbury, New Jersey, specializes in tumor-agnostic therapies and is leveraging decades of research in p53 biology.
Details
News Market Reaction – PMVP
The recorded move for PMVP in the trading session of this news was -1.43%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CRANBURY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President and Chief Executive Officer, will present on Wednesday, December 2, 2020 at the Evercore ISI 3rd Annual HealthCONx Conference. The presentation will also be available on PMV’s web site. Details on the presentation can be found below.
Evercore ISI 3rd Annual HealthCONx Conference
| Date: | Wednesday, December 2, 2020 |
| Time: | 1:00 PM ET |
| Webcast: | https://wsw.com/webcast/evercore11/pmvp/2394615 |
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 is mutated in approximately half of all cancer. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.
Contacts
For Investors:
Winston Kung
Chief Financial Officer
investors@pmvpharma.com
For Media:
Mariann Caprino
mcaprino@pmvpharma.com
(917) 242-1087
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.